Keywords: positive, ph, iii, results, spectrum, satraplatin, nasdaq-traded
Positive Ph III results for Spectrum's satraplatin
Article | 07 March 2005
Nasdaq-traded shares of US drugmaker Spectrum Pharmaceuticals closed up 3.3% at $6.52 on February 28, following positive results from a Phase III clinical ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Elan puts up formal "for sale" notice
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
